These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 9613761)

  • 1. Clozapine for dopaminergic-induced paraphilias in Parkinson's disease.
    Fernandez HH; Durso R
    Mov Disord; 1998 May; 13(3):597-8. PubMed ID: 9613761
    [No Abstract]   [Full Text] [Related]  

  • 2. Clozapine withdrawal symptoms in a Parkinson's disease patient.
    Zesiewicz TA; Borra S; Hauser RA
    Mov Disord; 2002 Nov; 17(6):1365-7. PubMed ID: 12465085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of drug-induced psychosis in Parkinson's disease with clozapine.
    Greene P; Cote L; Fahn S
    Adv Neurol; 1993; 60():703-6. PubMed ID: 8420214
    [No Abstract]   [Full Text] [Related]  

  • 4. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
    Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
    Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias.
    Facca A; Sanchez-Ramos J
    Mov Disord; 1996 May; 11(3):327-9. PubMed ID: 8723153
    [No Abstract]   [Full Text] [Related]  

  • 6. Nocturnal akathisia in Parkinson's disease: treatment with clozapine.
    Linazasoro G; Martí Massó JF; Suárez JA
    Mov Disord; 1993 Apr; 8(2):171-4. PubMed ID: 8474484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents.
    Seedat S; Kesler S; Niehaus DJ; Stein DJ
    Depress Anxiety; 2000; 11(4):185-6. PubMed ID: 10945141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated occurrence of clozapine-induced myocarditis in a patient with schizoaffective disorder and comorbid Parkinson's disease.
    Masopust J; Urban A; Valis M; Malý R; Tůma I; Hosák L
    Neuro Endocrinol Lett; 2009 Mar; 30(1):19-21. PubMed ID: 19300384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rebound psychosis: effect of discontinuation of antipsychotics in Parkinson's disease.
    Fernandez HH; Trieschmann ME; Okun MS
    Mov Disord; 2005 Jan; 20(1):104-5. PubMed ID: 15390047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing.
    Schindehütte J; Trenkwalder C
    Clin Neurol Neurosurg; 2007 Feb; 109(2):188-91. PubMed ID: 16949733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypersexual behaviour, frotteurism and delusional jealousy in a young parkinsonian patient during dopaminergic therapy with pergolide: A rare case of iatrogenic paraphilia.
    Cannas A; Solla P; Floris G; Tacconi P; Loi D; Marcia E; Marrosu MG
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Dec; 30(8):1539-41. PubMed ID: 16904253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clozapine: new preparation. A last resort for parkinsonian patients with psychosis.
    Prescrire Int; 2002 Feb; 11(57):1-6. PubMed ID: 11985366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pergolide mesylate: four years experience in Parkinson's disease.
    Tanner CM; Goetz CG; Glantz RH; Klawans HL
    Adv Neurol; 1987; 45():547-9. PubMed ID: 3825732
    [No Abstract]   [Full Text] [Related]  

  • 14. One-year trial of pergolide as an adjunct to Sinemet in treatment of Parkinson's disease.
    Diamond SG; Markham CH
    Adv Neurol; 1984; 40():537-9. PubMed ID: 6695633
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful re-challenge with clozapine following development of clozapine-induced cardiomyopathy.
    Floreani J; Bastiampillai T
    Aust N Z J Psychiatry; 2008 Aug; 42(8):747-8. PubMed ID: 18642408
    [No Abstract]   [Full Text] [Related]  

  • 16. Ziprasidone for drug-induced psychotic symptoms in Parkinson's Disease.
    Duggal HS; Singh I
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):583-4. PubMed ID: 18022304
    [No Abstract]   [Full Text] [Related]  

  • 17. [Optimum dosage of pergolide in patients with Parkinson's disease].
    Neshige R
    Rinsho Shinkeigaku; 2005 Apr; 45(4):328-30. PubMed ID: 15912805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clozapine treatment of persistent paroxysmal dyskinesia associated with concomitant paroxetine and sumatriptan use.
    Abraham JT; Brown R; Meltzer HY
    Biol Psychiatry; 1997 Jul; 42(2):144-6. PubMed ID: 9209732
    [No Abstract]   [Full Text] [Related]  

  • 19. Diabetes mellitus among parkinsonian patients treated chronically with clozapine.
    Fernandez HH; Friedman JH; Lansang MC; Factor SA; Molho ES; Coskun DJ
    Parkinsonism Relat Disord; 2004 Oct; 10(7):439-41. PubMed ID: 15465403
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetazolamide therapy of menstrual-related fluctuations in Parkinson's disease.
    Factor SA
    Mov Disord; 1993 Apr; 8(2):240-1. PubMed ID: 8474504
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.